HitGen

HitGen Inc. (Stock Code: 688222.SH, Stock Name: HitGen), headquartered in Chengdu, China, with subsidiaries in Cambridge, UK, and Houston, USA, is committed to building a world-class innovative biopharmaceutical enterprise. The company focuses on the discovery and optimization of small molecule and nucleic acid drugs. It has established an internationally leading DNA Encoded Library (DEL) technology platform (including DEL design, synthesis, screening, and extended applications) and expanded its core technology platforms to include Fragment-Based Drug Design/Structure-Based Drug Design (FBDD/SBDD), Small Molecule and Oligonucleotide (STO) technologies for oligonucleotide drug discovery, and Targeted Protein Degradation (TPD) technologies. Through diversified business models such as new drug R&D services, transfer of projects at various stages, and future drug commercialization, HitGen collaborates with hundreds of pharmaceutical companies, biotech firms, chemical companies, foundations, and research institutions worldwide. Currently, the company has multiple internal new drug projects at different clinical and preclinical stages.